Skip to content Skip to footer
Subscribe Now
NEWS

Servier Reports the CHMP’s Positive Opinion Voranigo (Vorasidenib) to Treat Grade 2 IDH-Mutant Glioma 

Shots:  The CHMP has recommended to Voranigo for treating patients (age: ≥12yrs.; wt≥ 40kg) with Gr2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation post-surgery but do not currently require radiotherapy or CT; anticipated EC decision in all 30 EEA states  The CHMP opinion is based on the global P-III (INDIGO) trial (N=331), which included…
July 24, 2025

Read more

New Drug Designations - November 2023
INSIGHTS+

New Drug Designations – November 2023

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EMA and China. This month’s report includes 3 biological drugs, 12 small molecules, 13 cell and gene therapies, 1 peptide, 3 exosome-based therapy and 4 devices  Atsena Therapeutics’ capsid AAV.SPR gene therapy, focused on the treatment of Leber congenital…
December 27, 2023

Read more

PharmaShots Interview Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy
VIEWPOINTS

PharmaShots Interview: Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

Shots:  Laurent spoke about the study design of its nanoparticle therapy to enhance the cancer-killing effect of radiation, which was presented at ASCO 2022 Laurent also highlighted how this nanoparticle therapy can be a potential radio enhancer in various tumor types and across lines of therapy The interview summarizes Nanobiotix’s vision to advance nanoparticles across…
August 10, 2022

Read more

PharmaShots Interview Kathy Davy, VP of Oncology at Thermo Fisher Scientific Shares Insights on the Real-World Data from Patients with NSCLC at ASCO 2022
VIEWPOINTS

PharmaShots Interview: Kathy Davy, VP of Oncology at Thermo Fisher Scientific Shares Insights on the Real-World Data from Patients with NSCLC at ASCO 2022

Shots: Kathy spoke about the major outcomes from the real-world evidence data presented at the ASCO 2022 Kathy also emphasized on how next-generation sequencing can improve genomic testing The interview gives a view of Thermo Fisher’s vision to bring targeted sequencing that provides faster results for clinicians Smriti: Tell us in detail about the key…
July 20, 2022

Read more